BRAF and breast carcinoma: She died from 12 weeks after initiation of dabrafenib and trametinib treatment.<h4>Conclusion</h4>To the best of our knowledge, this is the first report of BRAF mutation breast cancer treated with dabrafenib and trametinib and it heralds the possibility of targeted therapy for rare breast cancers.